Navigation Links
Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
Date:11/1/2011

DEERFIELD, Ill., Nov. 1, 2011 /PRNewswire/ -- Takeda Global Research & Development Center, Inc., (Takeda) announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 25, 2012 for the review of its investigational type 2 diabetes therapy alogliptin, and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.  

Currently, the FDA is reviewing the new drug applications (NDA) for the investigational therapies, which were resubmitted on July 25, 2011; the FDA has categorized these as Class 2 responses, requiring up to six months for review. Alogliptin is a selective dipeptidyl peptidase IV inhibitor (DPP-4i) under investigation in the United States (U.S.) for the treatment of type 2 diabetes as an adjunct to diet and exercise. Discovered by Takeda San Diego, Inc., alogliptin is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), which play a role in regulating blood glucose levels. Pioglitazone was approved in 1999 for the treatment of type 2 diabetes as an adjunct to diet and exercise. If approved, alogliptin/pioglitazone will be the first type 2 diabetes treatment option in the U.S. to include both a DPP-4 inhibitor and a thiazolidinedione (TZD) in a single tablet.

According to the International Diabetes Federation, a staggering 285 million individuals were living with diabetes worldwide in 2010.

"As recent figures indicate that diabetes continues to be a serious global health challenge, Takeda remains deeply committed to researching new and important therapeutic options for patients living with type 2 diabetes," said David Recker, M.D., senior vice president, clinical science, Takeda Global Research & Development Center. "Phase 3 studies have demonstrated that the combination of a
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
2. Takeda Completes Acquisition and Names New CEO of Nycomed
3. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
4. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
5. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
6. Takeda to Acquire Nycomed
7. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
8. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
9. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
10. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
11. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... LONDON , July 31, 2014 ... the medical industries, announced today the incorporation of genae UK in ... Kingdom has one of the largest medical device markets ... 2012 and it is projected to increase by a CAGR of ... in 2012, equal to 9.5% of GDP. Despite recessionary pressures, market ...
(Date:7/31/2014)... YORK , July 31, 2014 ... discovering and developing better, faster and affordable treatments, ... as Senior Vice President, External Affairs. Mr. Brock ... as Head of Major Donor Relations for WWF ... In his role, Mr. Brock will guide the ...
(Date:7/31/2014)... , July 31, 2014  Genomic Health, Inc. (Nasdaq: ... host a conference call and webcast on Thursday, August 7 ... 2014 financial results.  The call and webcast will follow the ... Conference Call Details To access the live conference ... phone, please dial (877) 303-7208 from the United ...
Breaking Medicine Technology:genae Opens Offices in London 2TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 3Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 4
... 27, 2012   VWR International, LLC , a global ... that it has signed an agreement to acquire ... in The Netherlands, France, Italy, Singapore, Malaysia and Vietnam. ... regulatory approval in Germany. With 30 years ...
... 2012  MetaStat, Inc. (OTCBB: MTST) announced today that ... patent applications and technology from the Albert Einstein ... license agreement covers U.S. Patent Application No. 12/998,237 ... Anti-Metastasis Treatment Efficacy"; inventors: Jeffrey Edward Segall, John ...
Cached Medicine Technology:VWR International, LLC Signs Agreement to Acquire basan Germany GmbH 2MetaStat, Inc. Executes Two New Licenses 2MetaStat, Inc. Executes Two New Licenses 3
(Date:7/31/2014)... Zensah®, a leading Miami based compression apparel company, ... , designed to help target tennis elbow, elbow tendonitis, ... for summer. The compression elbow sleeve is now available ... Zensah® fabric, the elbow sleeve is made ... no-slip cuff to ensure it stays in place, even ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 To further ... like to provide the following safety information regarding leaving ... a car can have deadly consequences. Because a child’s ... than those of adults, leaving children alone in a ... injury, and even death. , Statistics of Children Left ...
(Date:7/31/2014)... Most mommy blogs are simple family ... is to attract all mothers from all walks of ... group; whether its high fashion or child rearing. When ... on the Internet was so segmented. “I found myself ... topic and then search Google to get information on ...
(Date:7/31/2014)... A chance meeting at last April’s ASCAP “I ... Jimmy Robbins to Etymotic Research and their hearing ... in hearing wellness solutions, and maker of Music•PRO® ... Music•PRO® Electronic Earplugs have revolutionized hearing protection by ... natural hearing when hearing is not at risk. ...
(Date:7/31/2014)... News) -- Transplant surgeons often feel emotionally drained ... a new study suggests. Nearly half of ... a low sense of personal accomplishment and four ... researchers found. "Burnout is common in medicine, ... Dr. Marwan Abouljoud, director of the Henry Ford ...
Breaking Medicine News(10 mins):Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 2Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 3Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 2Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 3Health News:Mommylish Launches Its Website 2Health News:Country Star Jimmy Robbins Now Using Etymotic’s MusicPRO Electronic Earplugs 2Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2
... measurements into account , TUESDAY, Sept. 1 (HealthDay News) -- ... & World Report list of best hospitals for heart ... failure, researchers say. , "If you really want to know ... mortality and readmission, you should look directly at government statistics ...
... flu strains , TUESDAY, Sept. 1 (HealthDay News) -- Fears ... this year may be unfounded, say researchers at the University ... the swine flu pandemic did not take a virulent turn ... did spread more rapidly than the other viruses, confirming the ...
... , , ... Board: MLSS), the recognized leader in advanced injection technologies, today ... Chairman of the Board, succeeding Leonard Osser who had previously ... has also served as the interim Chief Executive Officer since ...
... , WARSAW, Ind., Sept. 1 Zimmer Holdings, Inc. (NYSE: ... following investor conferences during the month of September: , , ... Mass., on September 9, 2009, at 11:30 a.m. Eastern Time; , ... September 14, 2009, at 8:35 a.m. Eastern Time; and , ...
... , CARDIFF, Calif., Sept. 1 ... http://www.jedimindinc.com ) announced today that their Medical Division is ... in wheelchairs. An estimated 1.6 million Americans residing outside of ... Interview Survey on Disability (NHIS-D). Jedi Mind,s Medical Division is ...
... , ... Information Association (DIA) will host Personalized Medicine: Biomarkers and Diagnostics in Drug Development, Regulatory ... , ... September 1, 2009 -- The Drug Information Association (DIA) will host ...
Cached Medicine News:Health News:Government Best Source for U.S. Hospital Data, Study Finds 2Health News:Swine Flu May Be Less Dangerous Than Predicted: Study 2Health News:Swine Flu May Be Less Dangerous Than Predicted: Study 3Health News:Milestone Scientific Announces Key Leadership Changes 2Health News:Milestone Scientific Announces Key Leadership Changes 3Health News:Jedi Mind Medical Applications Division to Concentrate on Wheelchair Mobility Applications 2Health News:DIA Conference to Explore The Science and Scope of Personalized Medicine 2
... Reichert UNISTAT Bilirubinometer is ... for determining total bilirubin ... It quickly determines if ... needed by providing measurement ...
Biotest ELPHA (=Enzyme Linked Probe Hybridization Assay) for class I and class II HLA typing shows convincing advantages for your lab routine....
... Follicle-Stimulating Hormone (FSH) is a glygoprotein produced ... such as LH, TSH, and HCG, FSH consists ... FSH is a solid phase direct sandwich ELISA ... added to the wells coated with Mab to ...
... Class II Direct to High Res SSP kits provide ... single tray. Locus specific typing on a single tray ... Straight from genomic DNA to high resolution results, ... level typing with a single tray , Unique reaction ...
Medicine Products: